LCTX (Lineage Cell Therapeutics) Tax Rate %: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LCTX Lineage Cell Therapeutics Inc LCTX
78 GF Score
Price $1.14
GF Value $1.32
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Lineage Cell Therapeutics Tax Rate %?

Lineage Cell Therapeutics LCTX +3.64% 78 Tax Rate % is 0.00% as of Mar. 2026. GuruFocus rates LCTX with a GF Score™ of 78/100 and a GF Value™ of $1.32 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Tax Rate % is calculated as Tax Expense divided by its Pre-Tax Income. Lineage Cell Therapeutics's Tax Expense for the three months ended in Mar. 2026 was $0.00 Mil. Lineage Cell Therapeutics's Pre-Tax Income for the three months ended in Mar. 2026 was $-4.79 Mil. Therefore, Lineage Cell Therapeutics's Tax Rate % for the quarter that ended in Mar. 2026 was 0.00%.

Lineage Cell Therapeutics Tax Rate % Related Terms

Lineage Cell Therapeutics Tax Rate % Historical Data

* Premium members only.

The historical data trend for Lineage Cell Therapeutics's Tax Rate % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lineage Cell Therapeutics Tax Rate % Chart

Lineage Cell Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Tax Rate %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -2.10 7.74 0.00 7.69

Lineage Cell Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Tax Rate % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LCTX
78GF Score
Lineage Cell Therapeutics Inc LCTX
Tax Rate % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lineage Cell Therapeutics Tax Rate % Calculation

Tax Rate % is the ratio of tax expense divided by pretax income, usually presented in percent.

Lineage Cell Therapeutics's Tax Rate % for the fiscal year that ended in Dec. 2025 is calculated as

Tax Rate %=Tax Expense (A: Dec. 2025 )/Pre-Tax Income (A: Dec. 2025 )
=-5.28/-68.647
=7.69 %

Lineage Cell Therapeutics's Tax Rate % for the quarter that ended in Mar. 2026 is calculated as

Tax Rate %=Tax Expense (Q: Mar. 2026 )/Pre-Tax Income (Q: Mar. 2026 )
=0/-4.789
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Rate % →
What does a Tax Rate % of 0.00% mean?
Lineage Cell Therapeutics (LCTX) has a Tax Rate % of 0.00% as of Mar. 2026.
Is Lineage Cell Therapeutics' Tax Rate % too high?
Lineage Cell Therapeutics' current Tax Rate % is 0.00%. Overall, Lineage Cell Therapeutics has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lineage Cell Therapeutics' Tax Rate % compare to NWBO and ABEO?
Lineage Cell Therapeutics' Tax Rate % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Rate % for a Biotechnology company?
A good Tax Rate % depends on the Biotechnology industry context. However, Tax Rate % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Rate % mean?
A high Tax Rate % can signal that a stock is expensive relative to its fundamentals. Lineage Cell Therapeutics's current Tax Rate % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lineage Cell Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Lineage Cell Therapeutics (LCTX) is currently considered Modestly Undervalued. The stock's GF Value™ is $1.32, compared to a current price of $1.14 — trading 13.6% below its estimated fair value. The current Tax Rate % is 0.00%. Lineage Cell Therapeutics' overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Rate % calculated?
Tax Rate % is calculated from a company's financial statements. For Lineage Cell Therapeutics (LCTX), the current Tax Rate % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lineage Cell Therapeutics (LCTX) Overvalued in 2026?

Based on GuruFocus' analysis, Lineage Cell Therapeutics stock appears to be undervalued. The current stock price of $1.14 is trading 13.6% below its estimated GF Value™ of $1.32. GuruFocus considers Lineage Cell Therapeutics to be Modestly Undervalued.

Key valuation signals for LCTX:

  • Tax Rate %: 0.00%
  • GF Value™: $1.32 vs. price of $1.14 (13.6% below fair value)
  • GF Score™: 78/100 with 4 warning signs

No single metric tells the full story. See the LCTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lineage Cell Therapeutics Business Description

Other Exchanges LCTX:IsraelBT3:Germany
Address 2173 Salk Avenue, Suite 200, Carlsbad, CA, USA, 92008
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.
78GF Score

Get the complete analysis for LCTX

Tax Rate % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.14
Price
$1.32
GF Value